Showing 3451-3460 of 5381 results for "".
- Registration Opens for the Tell-All Tribune and Genesis Meetingshttps://practicaldermatology.com/news/Registration-Opens-Tell-All-Tribune-Genesis-Meetings/2471850/Registration is open for two Modern Aesthetics meetings that were overwhelmingly popular in 2024 and now will be held on the same weekend, June 20-21, at the W Hotel in Fort Lauderdale, Florida. The Tell-All Tribune: An Aesthetic Think Tank, which was an invitation-only event in its inaugu
- Almirall Hosts 16th Skin Academyhttps://practicaldermatology.com/news/Almirall-Hosts-16th-Skin-Academy/2471810/Almirall held the 16th edition of its Skin Academy conference for healthcare professionals in the field of dermatology on March 22-23 at the Barcelona International Convention Center in Spain. The event featured a comprehensive program aimed at sharing state-of-the-art scientific knowledge
- Lipid Metabolites Linked to Atopic Dermatitis Riskhttps://practicaldermatology.com/news/lipid-metabolites-linked-to-atopic-dermatitis-risk/2471714/A two-sample Mendelian randomization (TSMR) study has identified 13 lipid-related metabolite traits that influence the risk of developing atopic dermatitis (AD). Researchers examined genome-wide association study (GWAS) datase
- Study: Brepocitinib Reduces Inflammatory Markers in Cicatricial Alopeciahttps://practicaldermatology.com/news/study-brepocitinib-reduces-inflammatory-markers-in-cicatricial-alopecia/2471712/A recent phase 2a clinical trial showed brepocitinib was associated with a significant reduction in C-C motif chemokine ligand 5 (CCL5) expression and improved clinical severity scores in patients with cicatricial alopecia (CA).
- Meta-Analysis Validates SLNB Prediction Toolshttps://practicaldermatology.com/news/meta-analysis-validates-slnb-prediction-tools/2471653/A new systematic review and meta-analysis found several externally validated risk prediction models for sentinel lymph node biopsy (SLNB) positivity in melanoma with strong discriminative performance, though significant heterogeneity was observed.
- Colloidal Oatmeal Moisturizer in Managing Skin Microbiota: Studyhttps://practicaldermatology.com/news/colloidal-oatmeal-moisturizer-in-managing-skin-microbiota-study/2471650/A new in vitro study suggests a moisturizer containing colloidal oatmeal, patented filaggrin technology, niacinamide, and tocopheryl acetate selectively inhibits the growth and adhesion of Staphylococcus aureus (S. aureus) while promoting Staphylococcus epidermidis
- Upadacitinib Shows Superior Skin Clearance in Head and Neck Atopic Dermatitis Compared to Dupilumabhttps://practicaldermatology.com/news/Upadacitinib-Shows-Superior-Skin-Clearance-Head-Neck-Atopic-Dermatitis-Compared-Dupilumab/2471639/A numerically higher proportion of patients receiving upadacitinib achieved Eczema Area and Severity Index (EASI) 75/90/100 in the head and neck as early as 2 weeks after treatment was initiated compared with those receiving dupilumab in new Level Up study data present
- New Revenue Cycle Management Service Unveiledhttps://practicaldermatology.com/news/New-Revenue-Cycle-Management-Service-Unveiled/2471638/A new solution to alleviate the challenges posed by insurance claim denials and make it easier for providers to salvage denied claims and increase their reimbursement was on display at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, as Nextech previewed the late
- New Tapinarof Data Promising for Children and Perhaps Morehttps://practicaldermatology.com/news/New-Tapinarof-Data-Promising-Children-Perhaps-More/2471623/An analysis of the Phase 3 ADORING 3 study evaluating tapinarof cream, 1% once daily in adults and children 2 years of age and older with atopic dermatitis (AD) presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, demonstrated that AD disease activity re
- Further Positive Delgocitinib Data Presented at AADhttps://practicaldermatology.com/news/Further-Positive-Delgocitinib-Data-Presented-AAD/2471609/Late-breaking data presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, showcased responses in a subgroup of patients from the DELTA 1 and Delta 2 trials on lebrikizumab for chronic hand eczema. Alongside this presentation, new systemic exposure